Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 5
2011 9
2012 5
2013 4
2014 11
2015 14
2016 5
2017 13
2018 5
2019 7
2020 10
2021 9
2022 16
2023 18
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.
Liu W, Liu W, Zou H, Chen L, Huang W, Lv R, Xu Y, Liu H, Shi Y, Wang K, Wang Y, Xiong W, Deng S, Yi S, Sui W, Peng G, Ma Y, Wang H, Lv L, Wang J, Wei J, Qiu L, Zheng W, Zou D. Liu W, et al. Among authors: yi s. J Immunother Cancer. 2024 Apr 16;12(4):e008857. doi: 10.1136/jitc-2024-008857. J Immunother Cancer. 2024. PMID: 38631712 Free PMC article.
Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Zou H, Liu W, Wang X, Wang Y, Wang C, Qiu C, Liu H, Shan D, Xie T, Huang W, Sui W, Yi S, An G, Xu Y, Ma T, Wang J, Qiu L, Zou D. Zou H, et al. Among authors: yi s. J Immunother Cancer. 2024 Mar 4;12(3):e008450. doi: 10.1136/jitc-2023-008450. J Immunother Cancer. 2024. PMID: 38443094 Free article.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, Xu Y, Sui W, Deng S, Zou D, Du C, Yi S, van Rhee F, Barlogie B, Shaughnessy JD Jr, Anderson KC, Zhan F, Qiu L, An G. Mao X, et al. Among authors: yi s. Am J Hematol. 2024 Apr;99(4):523-533. doi: 10.1002/ajh.27207. Epub 2024 Jan 21. Am J Hematol. 2024. PMID: 38247315
Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial.
Xiong W, Lyu R, Yu Y, Wang T, Yan Y, Wang Y, Liu W, An G, Deng S, Xu Y, Sui W, Huang W, Zou D, Wang J, Qiu L, Yi S. Xiong W, et al. Among authors: yi s. Haematologica. 2024 May 1;109(5):1614-1618. doi: 10.3324/haematol.2023.284588. Haematologica. 2024. PMID: 38205507 Free PMC article. Clinical Trial. No abstract available.
Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Fan H, Wang B, Shi L, Pan N, Yan W, Xu J, Gong L, Li L, Liu Y, Du C, Cui J, Zhu G, Deng S, Sui W, Xu Y, Yi S, Hao M, Zou D, Chen X, Qiu L, An G. Fan H, et al. Among authors: yi s. Clin Cancer Res. 2024 Mar 15;30(6):1131-1142. doi: 10.1158/1078-0432.CCR-23-2767. Clin Cancer Res. 2024. PMID: 38170583 Free PMC article.
Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features.
Zou H, Liu W, Wang Y, Shan D, Xie T, Li R, Liu H, Huang W, Fu M, Wang T, Lv R, Deng S, Sui W, Xu Y, Yi S, An G, Qiu L, Zou D. Zou H, et al. Among authors: yi s. Chin Med J (Engl). 2023 Dec 7. doi: 10.1097/CM9.0000000000002940. Online ahead of print. Chin Med J (Engl). 2023. PMID: 38061986 No abstract available.
130 results